Contacts

Management

Carlo Incerti MD
Chairman 

Carlo Incerti, President of MolMed since September 2018, graduated in Medicine and Surgery in 1984 at the University of Modena. He most recently held the position of Head of Global Medical Affairs at Sanofi Genzyme and Chief Medical Officer, with oversight of 4 therapeutic areas: oncology, immunology, multiple sclerosis and rare diseases. He is Member of the Board of EuropaBio, the European Association for Bioindustries, and member of the Governing Board of IMI (Innovative Medicine Initiative), the largest public-private venture in the area of healthcare research, founded in 2008 thanks to a collaboration between the European Commission and the association of the European pharmaceutical industries (European Federation of Pharmaceutical Industries and Associations - EFPIA), with the aim of fostering innovation in the drug research and development process to satisfy unmet medical needs.

Riccardo Palmisano
CEO - Chief Executive Officer

Dr. Riccardo Palmisano, CEO at MolMed since December 2015, graduated in Medicine in 1985 at Parma University. His career in the Italian pharmaceutical industry started in 1986 at Farmitalia Carlo Erba (1986), he then moved on to Gruppo Menarini (1988) where he contributed to the development and internationalisation of the first Italian pharmaceutical Group, becoming Director of the Pharmaceutical Division Italy in 1993 and General Manager at Lusofarmaco in 1995. His career in multinational companies started in 2000: he set up the Italian branch of Shire Pharmaceutical (2000), then he was appointed Vice President Commercial Retail Market in GlaxoSmithKline Verona (2003) and, lastly, Vice President & General Manager Italy at Genzyme (2005), a U.S. biotech company specialized in research and development of orphan drugs for rare diseases. After the acquisition of Genzyme by Sanofi he was appointed Director of Business Strategy and Development at Sanofi Italia (2012-2013).
During his career, he successfully launched a large number of important products in many therapeutic areas, in both retail and hospital markets, participated and supported several international projects, and successfully negotiated pricing and reimbursement for several innovative drugs with the Italian Authorities. In 2008, he joined Assobiotec, the trade association part of Federchimica, that brings together Italian biotech companies, becoming Vice President, responsible for biotech pharma and health, in 2010. In 2016, was appointed President of Assobiotec.

Luca Alberici, PhD
CBO - Chief Business Officer 

Luca Alberici is Chief Business Officer since April 2015. He joined MolMed in 2006 and worked with growing responsibilities in R&D, contributing to the development of the Company’s “core” products and scouting and validation of potential drug candidates to enrich the portfolio. After a Master in Business Administration, he joined Bain & Company, a leading management consulting firm, where he was involved in strategic business planning, portfolio effectiveness, organization and process reengineering, due diligence and post-merger integration in healthcare and consumer good practices. Luca holds a Master degree in Medical, Molecular and Cellular Biotechnology from Vita-Salute San Raffaele University, a PhD in Cellular and Molecular Biology from the same institution and a Master In Business Administration from SDA Bocconi Milan.

Cynthia Giuliani
Human Resources & General Services

Cynthia Marina Giuliani joined MolMed as our director of human resources in February 2008.  She has 20 years experience in human resources, gained in multinational and biotech companies such as Roche and Liebert Hiross, and most recently in BioXell.
From 1988 to 1997 she worked for Roche in numerous human resources related functions. From 1998 to 2000 she worked as a consultant to a variety of companies. From 2000 to 2002 she worked for Liebert HIROSS S.p.A as that company’s European development manager, focusing on the recruitment and continuing education of personnel. Finally, before joining MolMed, Cynthia Giuliani worked for Bioxell, another biotechnology company, as the human resources director, responsible for the management, development and organisation of its human resources function.
Cynthia Giuliani received her BA Honours degree from the University of the Witwatersrand in South Africa.

Marco Manoni
Safety and Facility 

Marco Manoni joined MolMed as Director of Operations in September 2011 and is Facility Planning & Design Director since March 2013. He has more than 20 years experience in research, development, production and quality management  of  chemicals and  biologicals, diagnostics, nutraceuticals, pharmaceutical intermediates, active pharmaceutical ingredients (API) and investigational medicinal products (IMP). Before joining Molmed, he was  a member of the Board of Directors and the Chief Operating Officer at  RSM SpA, aR&D Company focused on development and production of intermediates, active pharmaceutical ingredients and investigational medicinal products, as well as Scientific Director of the Chemical-Pharmaceutical group INALCO, for 11 years. Previously, he was inter alia Development and Operation Manager  at PRIMM, one of the oldest Italian biotech companies.
Marco Manoni holds a Degree in Biology and a Master in Industrial Biotechnology from the State University of Milan.

Salvatore Calabrese
CFO - Administration, Finance & Control Director

Mr. Calabrese joined MolMed in September 2018 as Chief Financial Officer, following an extensive and significant international experience in public companies and in the biopharmaceutical sector, starting from PriceWaterhouseCooper where he was employed for seven years working in Milan, Italy and Boston, MA where, he served several clients of the biotech field listed on NASDAQ and NYSE, and subsequently at Novuspharma S.p.A., a subsidiary of Cell Therapeutics, Inc. (NASDAQ: CTIC), as Accounting & Finance Manager. From 2005 to 2014 he worked in Gentium S.p.A. (NASDAQ: GEN) where he was instrumental to the listing of the company on Nasdaq, covering various roles including Senior Vice President and Chief Financial Officer and Chief Operating Officer, supervising all of the company's corporate operations. Following the acquisition of Gentium by Jazz Pharmaceuticals (NASDAQ: JAZZ), he worked as General Manager and Site Leader for the Italian Operation at the Italian branch. He was also member of the Board of Directors of Gentium S.p.A. Jazz Pharmaceuticals Italy S.p.A. and Jazz Healthcare Italy S.r.l

Simona Rovetta
Operations Director

Simona Rovetta is Operations Director in MolMed. She joins MolMed since 2008 as CMC Manager for manufacturing and testing activities performed at subcontractors. From 2011, she is Quality Assurance Manager in MolMed.
She has about 15 years’ experience in QA area mainly as Validation Manager in Engineering and International Pharmaceutical companies working in direct contact with different functional areas as GMP Manufacturing, Supply Chain and Engineering.
Simona Rovettas has a degree in Chemistry.

 

Giuliana Vallanti, PhD
Development & Quality Control Director

Giuliana Vallanti is Development and Quality Control Director and Qualified Person in MolMed.
She joined MolMed in 2005 and worked with growing responsibilities in Development and Quality Control units, contributing to the development of processes and assays in cell and gene therapy field. She has main experiences in the development and industrialization of T- and haematopietic cells transduction processes with lentiviral and retroviral vectors. She worked on the development of GMP processes for large scale vectors production and purification.
She holds a degree in Biology from Università degli Studi - Urbino and a Ph.D. in biochemical and pharmacological methods with a study on Lentiviral Vector for gene therapy anti HIV-1.

Tiziano Andreoli
Information Technology 

Tiziano Andreoli is Information Technology Director since January 2016. He joined MolMed in 2011 and he’s always worked in IT groups in different roles with growing responsibilities, focusing his activities in governance and assessments, process and data flows, reverse engineering, software analysis, re-engineering and development. Tiziano holds a degree in Electronic Engineering from Università degli Studi in Brescia.

 

 

Antonio Lambiase MD
Clinical Development 

Antonio Lambiase joined MolMed in March 2007. He previously worked for over fifteen years at Roche in the areas of oncology and haematology as medical responsible for clinical development of several biological and molecular targeted compounds, including cancer biotherapeutics, haematopoietic growth factors, therapeutic monoclonal antibodies and antiangiogenesis agents. Before that, he spent three years as a research fellow at the Medical Oncology Unit of National Cancer Institute of Milan.
Antonio Lambiase received his degree in Medicine from University of Naples, where he completed his postgraduate studies and specialisation.

Catia Traversari
Head of Research 

Catia Traversari joined MolMed in January 2002. Prior to this date, she held the position of head of Cancer Immunotherapy and Gene Therapy in Genera Spa. She has over 15 years experience in tumor immunology and immunotherapy research.
Catia was directly involved in the molecular cloning of the first human tumor antigen gene during her stage at the Ludwig Institute. She is the author of more than 70 publications and inventor of several of the company's core technologies. She joined the San Raffaele Scientific Institute in 1991 and was among the founding members of the Gene Therapy Programme. Previously, Catia Traversari served as Visiting Scientist at the Ludwig Institute for Cancer Research in Bruxelles and as research associate at the Istituto dei Tumori in Milan, one of the leading non-profit cancer research centres in Italy.
Catia Traversari graduated in Biology at the University of Milan.

MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italy | Phone +39 0221277.1 - Fax +39 02 21277.325 | info@molmed.com - www.molmed.com
Privacy & Cookie Policy | Suppliers' Privacy Policy | Customers' Privacy Policy
Share capital € 21,819,020.83 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159